PE20170145A1 - Combinacion - Google Patents
CombinacionInfo
- Publication number
- PE20170145A1 PE20170145A1 PE2016002228A PE2016002228A PE20170145A1 PE 20170145 A1 PE20170145 A1 PE 20170145A1 PE 2016002228 A PE2016002228 A PE 2016002228A PE 2016002228 A PE2016002228 A PE 2016002228A PE 20170145 A1 PE20170145 A1 PE 20170145A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- pemphigus
- las191954
- rigosertib
- duvelisib
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000017520 skin disease Diseases 0.000 abstract 2
- QUMWKKVIZAIAHU-LBPRGKRZSA-N 2-[(1s)-1-[(6-amino-5-cyanopyrimidin-4-yl)amino]ethyl]-4-oxo-3-phenylpyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile Chemical compound N([C@@H](C)C=1N(C(=O)C2=C(C#N)C=CN2N=1)C=1C=CC=CC=1)C1=NC=NC(N)=C1C#N QUMWKKVIZAIAHU-LBPRGKRZSA-N 0.000 abstract 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 abstract 1
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 abstract 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- 206010048768 Dermatosis Diseases 0.000 abstract 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- 201000011152 Pemphigus Diseases 0.000 abstract 1
- 241000721454 Pemphigus Species 0.000 abstract 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- 229960002170 azathioprine Drugs 0.000 abstract 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 229950004949 duvelisib Drugs 0.000 abstract 1
- 229960003445 idelalisib Drugs 0.000 abstract 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 abstract 1
- 229960000598 infliximab Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229960000485 methotrexate Drugs 0.000 abstract 1
- 229960004584 methylprednisolone Drugs 0.000 abstract 1
- 201000001976 pemphigus vulgaris Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005205 prednisolone Drugs 0.000 abstract 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 abstract 1
- OWBFCJROIKNMGD-BQYQJAHWSA-N rigosertib Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC(O)=O)=C1 OWBFCJROIKNMGD-BQYQJAHWSA-N 0.000 abstract 1
- 229950006764 rigosertib Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se refiere a una composicion farmaceutica que comprende: a) un compuesto que es un inhibidor de fosfoinositido 3-quinasa delta tal como LAS191954, idelalisib, duvelisib, rigosertib, entre otros; y b) un corticosteroide tal como prednisolona, metilprednisolona, dexametasona, entre otros. Adicionalmente dicha composicion comprende al menos otros compuestos activos tales como metotrexato, azatioprina, ciclofosfamida, infliximab, entre otros. Dicha composicion es util en el tratamiento de una enfermedad cutanea tal como penfigo vulgar, penfigo vegetante, dermatosis por IgA intercelular, entre otras.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382192 | 2014-05-27 | ||
| EP14382401 | 2014-10-17 | ||
| EP14382400 | 2014-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170145A1 true PE20170145A1 (es) | 2017-03-10 |
Family
ID=53269467
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016002228A PE20170145A1 (es) | 2014-05-27 | 2015-05-21 | Combinacion |
| PE2016002230A PE20170385A1 (es) | 2014-05-27 | 2015-05-21 | Sales de adicion de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016002230A PE20170385A1 (es) | 2014-05-27 | 2015-05-21 | Sales de adicion de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20170151264A1 (es) |
| EP (3) | EP3148999A1 (es) |
| JP (3) | JP2017516798A (es) |
| KR (3) | KR20170007760A (es) |
| CN (3) | CN106414449A (es) |
| AU (3) | AU2015266193A1 (es) |
| BR (1) | BR112016024538A2 (es) |
| CA (3) | CA2944611A1 (es) |
| CL (2) | CL2016002970A1 (es) |
| CR (3) | CR20160538A (es) |
| EA (3) | EA201692435A1 (es) |
| IL (3) | IL247073A0 (es) |
| MA (3) | MA39828A (es) |
| MD (3) | MD20160137A2 (es) |
| MX (3) | MX2016014864A (es) |
| PE (2) | PE20170145A1 (es) |
| PH (3) | PH12016502252A1 (es) |
| SG (3) | SG11201606762PA (es) |
| TW (3) | TW201625260A (es) |
| UY (3) | UY36152A (es) |
| WO (3) | WO2015181055A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5869222B2 (ja) | 2008-01-04 | 2016-02-24 | インテリカイン， エルエルシー | 特定の化学的実体、組成物および方法 |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| SG10201600179RA (en) | 2011-01-10 | 2016-02-26 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| ES2873001T3 (es) | 2011-09-02 | 2021-11-03 | Incyte Holdings Corp | Heterociclaminas como inhibidores de PI3K |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| HUE040126T2 (hu) | 2012-11-01 | 2019-02-28 | Infinity Pharmaceuticals Inc | Rákok kezelése PI3 kináz izoform modulátorok alkalmazásával |
| ES2797376T3 (es) | 2013-01-24 | 2020-12-02 | Palvella Therapeutics Inc | Composiciones para la administración transdérmica de inhibidores de mTOR |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| JP6816005B2 (ja) | 2015-02-27 | 2021-01-20 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉ３ｋ阻害剤の塩及びその調製のためのプロセス |
| ES2981704T3 (es) | 2016-04-27 | 2024-10-10 | Abbvie Mfg Management Unlimited Company | Métodos de tratamiento de enfermedades en las que la actividad de IL-13 es perjudicial mediante la utilización de anticuerpos anti-IL-13 |
| RU2018140001A (ru) | 2016-05-18 | 2020-06-18 | Пикур Терапьютикс Аг | Лечение повреждений кожи |
| GB201608797D0 (en) * | 2016-05-19 | 2016-07-06 | Ucb Biopharma Sprl | Therapeutic use |
| CN107456454A (zh) * | 2016-06-06 | 2017-12-12 | 先声药业有限公司 | 一种预防或治疗炎性疾病的药物组合物 |
| UA125216C2 (uk) | 2016-06-24 | 2022-02-02 | Інфініті Фармасьютікалз, Інк. | Комбінована терапія |
| EP3565520A4 (en) | 2017-01-06 | 2020-08-19 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE |
| GB201708856D0 (en) * | 2017-06-02 | 2017-07-19 | Ucb Biopharma Sprl | Seletalisib crystalline forms |
| SG11202004589SA (en) | 2017-11-23 | 2020-06-29 | Piqur Therapeutics Ag | Treatment of skin disorders |
| EP3817743A4 (en) | 2018-07-02 | 2022-07-06 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE |
| US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
| CN113440614A (zh) * | 2020-03-26 | 2021-09-28 | 长沙晶易医药科技有限公司 | 一种用于治疗类风湿性关节炎的组合物及其应用 |
| KR102733299B1 (ko) * | 2021-11-05 | 2024-11-25 | 연세대학교 산학협력단 | 피부-특이적 T 세포(skin-specific T cell)의 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물 |
| AR127966A1 (es) * | 2021-12-16 | 2024-03-13 | Incyte Corp | Formulaciones tópicas de inhibidores de pi3k-delta |
| TWI823476B (zh) * | 2022-07-15 | 2023-11-21 | 中化合成生技股份有限公司 | 托法替尼檸檬酸鹽的製備方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008501707A (ja) * | 2004-06-04 | 2008-01-24 | アイコス、コーポレーション | マスト細胞障害を処置するための方法 |
| EP2351745A1 (en) * | 2005-08-26 | 2011-08-03 | Merck Serono S.A. | Pyrazine derivatives and use as PI3K inhibitors |
| BRPI1012333A2 (pt) * | 2009-03-24 | 2016-03-29 | Gilead Calistoga Llc | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso |
| EP2518070A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
-
2015
- 2015-05-21 BR BR112016024538A patent/BR112016024538A2/pt not_active Application Discontinuation
- 2015-05-21 SG SG11201606762PA patent/SG11201606762PA/en unknown
- 2015-05-21 MD MDA20160137A patent/MD20160137A2/ro not_active Application Discontinuation
- 2015-05-21 CA CA2944611A patent/CA2944611A1/en not_active Abandoned
- 2015-05-21 CN CN201580028179.4A patent/CN106414449A/zh active Pending
- 2015-05-21 KR KR1020167033149A patent/KR20170007760A/ko not_active Withdrawn
- 2015-05-21 WO PCT/EP2015/061312 patent/WO2015181055A1/en not_active Ceased
- 2015-05-21 WO PCT/EP2015/061307 patent/WO2015181052A1/en not_active Ceased
- 2015-05-21 KR KR1020167033156A patent/KR20170010369A/ko not_active Withdrawn
- 2015-05-21 EP EP15725294.1A patent/EP3148999A1/en not_active Withdrawn
- 2015-05-21 CN CN201580028234.XA patent/CN106456777A/zh active Pending
- 2015-05-21 MA MA039828A patent/MA39828A/fr unknown
- 2015-05-21 EA EA201692435A patent/EA201692435A1/ru unknown
- 2015-05-21 MA MA039827A patent/MA39827A/fr unknown
- 2015-05-21 US US15/313,737 patent/US20170151264A1/en not_active Abandoned
- 2015-05-21 CA CA2941436A patent/CA2941436A1/en not_active Abandoned
- 2015-05-21 JP JP2016569769A patent/JP2017516798A/ja active Pending
- 2015-05-21 US US15/313,722 patent/US20170189409A1/en not_active Abandoned
- 2015-05-21 JP JP2016569768A patent/JP2017516797A/ja active Pending
- 2015-05-21 MA MA039829A patent/MA39829A/fr unknown
- 2015-05-21 EP EP15725295.8A patent/EP3148585A1/en not_active Withdrawn
- 2015-05-21 EA EA201692436A patent/EA201692436A1/ru unknown
- 2015-05-21 EA EA201692437A patent/EA201692437A1/ru unknown
- 2015-05-21 AU AU2015266193A patent/AU2015266193A1/en not_active Abandoned
- 2015-05-21 AU AU2015266190A patent/AU2015266190A1/en not_active Abandoned
- 2015-05-21 CN CN201580028312.6A patent/CN107074862A/zh active Pending
- 2015-05-21 CR CR20160538A patent/CR20160538A/es unknown
- 2015-05-21 SG SG11201606763VA patent/SG11201606763VA/en unknown
- 2015-05-21 PE PE2016002228A patent/PE20170145A1/es not_active Application Discontinuation
- 2015-05-21 CR CR20160537A patent/CR20160537A/es unknown
- 2015-05-21 MX MX2016014864A patent/MX2016014864A/es unknown
- 2015-05-21 AU AU2015266191A patent/AU2015266191A1/en not_active Abandoned
- 2015-05-21 CR CR20160536A patent/CR20160536A/es unknown
- 2015-05-21 KR KR1020167032089A patent/KR20170012236A/ko not_active Withdrawn
- 2015-05-21 MX MX2016014904A patent/MX2016014904A/es unknown
- 2015-05-21 SG SG11201607950SA patent/SG11201607950SA/en unknown
- 2015-05-21 MD MDA20160138A patent/MD20160138A2/ro not_active Application Discontinuation
- 2015-05-21 WO PCT/EP2015/061308 patent/WO2015181053A1/en not_active Ceased
- 2015-05-21 EP EP15726063.9A patent/EP3148586A1/en not_active Withdrawn
- 2015-05-21 US US15/313,762 patent/US20170158699A1/en not_active Abandoned
- 2015-05-21 JP JP2016569770A patent/JP2017516799A/ja active Pending
- 2015-05-21 MX MX2016014861A patent/MX2016014861A/es unknown
- 2015-05-21 PE PE2016002230A patent/PE20170385A1/es not_active Application Discontinuation
- 2015-05-21 MD MDA20160132A patent/MD20160132A2/ro not_active Application Discontinuation
- 2015-05-21 CA CA2941429A patent/CA2941429A1/en not_active Abandoned
- 2015-05-25 TW TW104116634A patent/TW201625260A/zh unknown
- 2015-05-25 TW TW104116629A patent/TW201625258A/zh unknown
- 2015-05-25 TW TW104116630A patent/TW201625259A/zh unknown
- 2015-06-03 UY UY0001036152A patent/UY36152A/es not_active Application Discontinuation
- 2015-06-03 UY UY0001036151A patent/UY36151A/es not_active Application Discontinuation
- 2015-06-03 UY UY0001036153A patent/UY36153A/es not_active Application Discontinuation
-
2016
- 2016-08-02 IL IL247073A patent/IL247073A0/en unknown
- 2016-08-02 IL IL247072A patent/IL247072A0/en unknown
- 2016-09-19 IL IL247901A patent/IL247901A0/en unknown
- 2016-11-11 PH PH12016502252A patent/PH12016502252A1/en unknown
- 2016-11-11 PH PH12016502256A patent/PH12016502256A1/en unknown
- 2016-11-11 PH PH12016502255A patent/PH12016502255A1/en unknown
- 2016-11-21 CL CL2016002970A patent/CL2016002970A1/es unknown
- 2016-11-21 CL CL2016002971A patent/CL2016002971A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170145A1 (es) | Combinacion | |
| MX2017010773A (es) | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer. | |
| DOP2016000194A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| ECSP17028463A (es) | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 | |
| CO2018000660A2 (es) | Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol | |
| CO2017004649A2 (es) | Esteroides neuroactivos para trastornos del snc | |
| CO2017009298A2 (es) | Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8 | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| MX2020011104A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| PH12016501788B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| ECSP17035415A (es) | 2-Amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de BACE1 | |
| BR112017001221A2 (pt) | derivados de indolizina que são aplicáveis a doenças neurodegenerativas | |
| CL2017000040A1 (es) | Inhibidores de aldosterona sintasa. | |
| CO2017008765A2 (es) | Nueva triterpenona c-3 con derivados de amida inversa c-17 como inhibidores de vih | |
| PH12017500710A1 (en) | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | |
| MX2023012640A (es) | Uso de profarmacos de riluzol para tratar ataxias. | |
| SV2017005354A (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| EA201692020A1 (ru) | Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях | |
| GT201400146A (es) | Composiciones farmacéuticas tópicas que comprenden bexaroteno y corticosteroides | |
| BR112016016098A2 (pt) | Compostos orgânicos | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| GT201600190A (es) | Compuestos químicos | |
| CR20150190A (es) | Composición sinérgica de nitazoxanida y mebendazol, procesos para preparla y el uso de dicha composición para el tratamiento de la parasitosis humana | |
| MX2020002812A (es) | Abx196 para usarse en el tratamiento del cancer de vejiga. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |